Mathematical Modeling of Protein Misfolding Mechanisms in Neurological Diseases: A Historical Overview

Protein misfolding refers to a process where proteins become structurally abnormal and lose their specific 3-dimensional spatial configuration. The histopathological presence of misfolded protein (MP) aggregates has been associated as the primary evidence of multiple neurological diseases, including Prion diseases, Alzheimer’s disease, Parkinson’s disease, and Creutzfeldt-Jacob disease. However, the exact mechanisms of MP aggregation and propagation, as well as their impact in the long-term patient’s clinical condition are still not well understood. With this aim, a variety of mathematical models has been proposed for a better insight into the kinetic rate laws that govern the microscopic processes of protein aggregation. Complementary, another class of large-scale models rely on modern molecular imaging techniques for describing the phenomenological effects of MP propagation over the whole brain. Unfortunately, those neuroimaging-based studies do not take full advantage of the tremendous capabilities offered by the chemical kinetics modeling approach. Actually, it has been barely acknowledged that the vast majority of large-scale models have foundations on previous mathematical approaches that describe the chemical kinetics of protein replication and propagation. The purpose of the current manuscript is to present a historical review about the development of mathematical models for describing both microscopic processes that occur during the MP aggregation and large-scale events that characterize the progression of neurodegenerative MP-mediated diseases.

[1]  J. Hofrichter,et al.  Kinetics of sickle hemoglobin polymerization. II. A double nucleation mechanism. , 1985, Journal of molecular biology.

[2]  D. Kirschner,et al.  Kinetic theory of fibrillogenesis of amyloid beta-protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Toshiki Uchihara,et al.  Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies , 2015, Acta Neuropathologica.

[4]  Andrea Tosin,et al.  Alzheimer's disease: a mathematical model for onset and progression. , 2015, Mathematical medicine and biology : a journal of the IMA.

[5]  Vincenzo Martorana,et al.  Protofibril Formation of Amyloid β-Protein at Low pH via a Non-cooperative Elongation Mechanism* , 2005, Journal of Biological Chemistry.

[6]  Tuomas P. J. Knowles,et al.  Mean-field master equation formalism for biofilament growth , 2014 .

[7]  L. Edelstein-Keshet,et al.  Exploring the formation of Alzheimer's disease senile plaques in silico. , 2002, Journal of theoretical biology.

[8]  Raimon Sabaté,et al.  Evidence of the existence of micelles in the fibrillogenesis of beta-amyloid peptide. , 2005, The journal of physical chemistry. B.

[9]  J. Trojanowski,et al.  Spreading of pathology in neurodegenerative diseases: a focus on human studies , 2015, Nature Reviews Neuroscience.

[10]  F. Ferrone,et al.  Analysis of protein aggregation kinetics. , 1999, Methods in enzymology.

[11]  H Fraser,et al.  Scrapie in the central nervous system: neuroanatomical spread of infection and Sinc control of pathogenesis. , 1992, The Journal of general virology.

[12]  R J Fletterick,et al.  Structural clues to prion replication. , 1994, Science.

[13]  Paul M. Thompson,et al.  Localizing Sources of Brain Disease Progression with Network Diffusion Model , 2016, IEEE Journal of Selected Topics in Signal Processing.

[14]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[15]  Dietmar Oelz,et al.  Size distribution dependence of prion aggregates infectivity. , 2009, Mathematical biosciences.

[16]  Peter T. Lansbury,et al.  Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease† , 1999 .

[17]  C. Dobson Protein folding and misfolding , 2003, Nature.

[18]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[19]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[20]  Tuomas P. J. Knowles,et al.  On the lag phase in amyloid fibril formation , 2015, Physical chemistry chemical physics : PCCP.

[21]  R M Murphy,et al.  Probing the kinetics of beta-amyloid self-association. , 2000, Journal of structural biology.

[22]  Carole J Proctor,et al.  Aggregation, impaired degradation and immunization targeting of amyloid-beta dimers in Alzheimer’s disease: a stochastic modelling approach , 2012, Molecular Neurodegeneration.

[23]  Laurent Pujo-Menjouet,et al.  Analysis of a model for the dynamics of prions , 2005 .

[24]  Lawrence M. Wein,et al.  The Impact of Novel Treatments on A\03B2 Burden in Alzheimer's Disease: Insights From a Mathematical Model , 2015 .

[25]  Glenn F. Webb,et al.  Analysis of a model for the dynamics of prions II , 2005 .

[26]  V. Calvez,et al.  Prion dynamics with size dependency–strain phenomena , 2010, Journal of biological dynamics.

[27]  F. Ferrone,et al.  Kinetics of nucleation-controlled polymerization. A perturbation treatment for use with a secondary pathway. , 1984, Biophysical journal.

[28]  Alan C. Evans,et al.  Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer’s disease , 2017, NeuroImage.

[29]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[30]  P E Fraser,et al.  A kinetic model for amyloid formation in the prion diseases: importance of seeding. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Michele Vendruscolo,et al.  An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer’s disease , 2016, Science Advances.

[32]  F. Oosawa,et al.  A theory of linear and helical aggregations of macromolecules. , 1962, Journal of molecular biology.

[33]  M. C. Tesi,et al.  A QUALITATIVE MODEL FOR AGGREGATION-FRAGMENTATION AND DIFFUSION OF β-AMYLOID IN ALZHEIMER’S DISEASE , 2014 .

[34]  Michele Vendruscolo,et al.  A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity , 2017, Proceedings of the National Academy of Sciences.

[35]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[36]  V. Jansen,et al.  Designing drugs to stop the formation of prion aggregates and other amyloids. , 2000, Biophysical chemistry.

[37]  Lawrence M. Wein,et al.  A mathematical model of the impact of novel treatments on the Aβ burden in the Alzheimer’s brain, CSF and plasma , 2015, Bulletin of mathematical biology.

[38]  C. Dobson,et al.  Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. , 2017, Annual review of biochemistry.

[39]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[40]  C. Iadecola,et al.  The Pathobiology of Vascular Dementia , 2013, Neuron.

[41]  Alexander K. Buell,et al.  Spatial propagation of protein polymerization. , 2014, Physical review letters.

[42]  Michele Vendruscolo,et al.  Chemical kinetics for drug discovery to combat protein aggregation diseases. , 2014, Trends in pharmacological sciences.

[43]  D. Selkoe,et al.  Nasal administration of amyloid‐β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease , 2000, Annals of neurology.

[44]  Raibatak Das,et al.  Modeling Effect of a γ-Secretase Inhibitor on Amyloid-β Dynamics Reveals Significant Role of an Amyloid Clearance Mechanism , 2011, Bulletin of mathematical biology.

[45]  Franziska Matthäus THE SPREAD OF PRION DISEASES IN THE BRAIN — MODELS OF REACTION AND TRANSPORT ON NETWORKS , 2009 .

[46]  M. Diamond,et al.  Prion-like mechanisms in neurodegenerative diseases , 2010, Nature Reviews Neuroscience.

[47]  Chengjie Xiong,et al.  Age and amyloid effects on human central nervous system amyloid‐beta kinetics , 2015, Annals of neurology.

[48]  Tuomas P. J. Knowles,et al.  The Kinetics and Mechanisms of Amyloid Formation , 2013 .

[49]  M. Eigen,et al.  Prionics or the kinetic basis of prion diseases. , 1996, Biophysical chemistry.

[50]  Michele Vendruscolo,et al.  Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments. , 2011, The Journal of chemical physics.

[51]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.

[52]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[53]  M. Weiner,et al.  A Network Diffusion Model of Disease Progression in Dementia , 2012, Neuron.

[54]  Adam Douglass,et al.  Mechanism of Prion Propagation: Amyloid Growth Occurs by Monomer Addition , 2004, PLoS biology.

[55]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[56]  S. Prusiner Novel proteinaceous infectious particles cause scrapie. , 1982, Science.

[57]  P. Lantos,et al.  The spatial patterns of prion protein deposits in Creutzfeldt–Jakob disease: comparison with β-amyloid deposits in Alzheimer's disease , 2001, Neuroscience Letters.

[58]  David C. Krakauer,et al.  The spatial dynamics of prion disease , 1998, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[59]  Martin A. Nowak,et al.  Prion infection dynamics , 1998 .

[60]  Dennis W. Dickson,et al.  Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies , 2015, Acta Neuropathologica.

[61]  George B. Benedek,et al.  Kinetic theory of fibrillogenesis of amyloid β-protein , 1997 .

[62]  Charles Duyckaerts,et al.  Propagation of Aß pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies , 2015, Acta Neuropathologica.

[63]  Michele Vendruscolo,et al.  Nucleated polymerization with secondary pathways. II. Determination of self-consistent solutions to growth processes described by non-linear master equations. , 2011, The Journal of chemical physics.

[64]  R. Murphy,et al.  A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. , 2001, Biophysical journal.

[65]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[66]  Harry LeVine,et al.  The cerebral proteopathies , 2000, Neurobiology of Aging.

[67]  Michele Vendruscolo,et al.  Selective targeting of primary and secondary nucleation pathways in Aβ42 aggregation using a rational antibody scanning method , 2017, Science Advances.

[68]  Thorsten Pöschel,et al.  Kinetics of prion growth. , 2003, Biophysical journal.

[69]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[70]  Regina M Murphy,et al.  Peptide aggregation in neurodegenerative disease. , 2002, Annual review of biomedical engineering.

[71]  Michele Vendruscolo,et al.  Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism , 2013, Proceedings of the National Academy of Sciences.

[72]  Thierry Goudon,et al.  Scaling limit of a discrete prion dynamics model , 2009, 0907.2297.

[73]  Stephen J. DeArmond,et al.  Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication , 1990, Cell.

[74]  Leah Edelstein-Keshet,et al.  Chemotactic signaling, microglia, and Alzheimer’s disease senile plaques: Is there a connection? , 2003, Bulletin of mathematical biology.

[75]  S. Prusiner,et al.  Molecular biology of prion diseases , 1991, Science.

[76]  Michael Weiner,et al.  Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimer's Disease. , 2015, Cell reports.

[77]  Ishwar K. Puri,et al.  Mathematical Modeling for the Pathogenesis of Alzheimer's Disease , 2010, PloS one.

[78]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[79]  TIKVAH ALPER,et al.  Does the Agent of Scrapie Replicate without Nucleic Acid ? , 1967, Nature.

[80]  Ronald Melki,et al.  Prion-like transmission of protein aggregates in neurodegenerative diseases , 2010, Nature Reviews Molecular Cell Biology.

[81]  Andrea Tosin,et al.  Microscopic and macroscopic models for the onset and progression of Alzheimer's disease , 2017, 1703.10774.

[82]  Michele Vendruscolo,et al.  Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation , 2016, Nature Communications.

[83]  Michele Vendruscolo,et al.  Nucleated polymerization with secondary pathways. III. Equilibrium behavior and oligomer populations. , 2011, The Journal of chemical physics.

[84]  Carole J. Proctor,et al.  Investigating Interventions in Alzheimer's Disease with Computer Simulation Models , 2013, PloS one.

[85]  Murray Grossman,et al.  Stages of pTDP‐43 pathology in amyotrophic lateral sclerosis , 2013, Annals of neurology.

[86]  Thomas C T Michaels,et al.  Dynamics of protein aggregation and oligomer formation governed by secondary nucleation. , 2015, The Journal of chemical physics.

[87]  Christopher M. Dobson,et al.  Protein-misfolding diseases: Getting out of shape , 2002, Nature.

[88]  Laurent Pujo-Menjouet,et al.  A mathematical analysis of the dynamics of prion proliferation. , 2006, Journal of theoretical biology.

[89]  Mathias Jucker,et al.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases , 2013, Nature.

[90]  Franziska Matthäus,et al.  Diffusion versus network models as descriptions for the spread of prion diseases in the brain. , 2006, Journal of theoretical biology.

[91]  Richard D. Leapman,et al.  Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid Fibrils , 2005, Science.

[92]  Sara Linse,et al.  Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides , 2014, Proceedings of the National Academy of Sciences.

[93]  Yves Achdou,et al.  A qualitative model for aggregation and diffusion of $$\beta $$-amyloid in Alzheimer’s disease , 2013, Journal of mathematical biology.

[94]  Christoph Walker,et al.  On the solvability of a mathematical model for prion proliferation , 2006 .

[95]  Regina M. Murphy,et al.  Probing the Kinetics of β-Amyloid Self-Association , 2000 .

[96]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[97]  D C Krakauer,et al.  Mapping the parameters of prion-induced neuropathology. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[98]  Tuomas P. J. Knowles,et al.  An Analytical Solution to the Kinetics of Breakable Filament Assembly , 2009, Science.

[99]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.

[100]  Michele Vendruscolo,et al.  Hamiltonian Dynamics of Protein Filament Formation. , 2016, Physical review letters.

[101]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[102]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[103]  Tuomas P. J. Knowles,et al.  Quantitative analysis of intrinsic and extrinsic factors in the aggregation mechanism of Alzheimer-associated Aβ-peptide , 2016, Scientific Reports.

[104]  F. Brauer,et al.  Mathematical Models in Population Biology and Epidemiology , 2001 .

[105]  Alan C. Evans,et al.  Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders , 2014, PLoS Comput. Biol..

[106]  Suzanne S. Sindi,et al.  A study in nucleated polymerization models of protein aggregation , 2015, Appl. Math. Lett..

[107]  Michele Vendruscolo,et al.  From macroscopic measurements to microscopic mechanisms of protein aggregation. , 2012, Journal of molecular biology.

[108]  M A Nowak,et al.  Quantifying the kinetic parameters of prion replication. , 1999, Biophysical chemistry.

[109]  Tuomas P. J. Knowles,et al.  Scaling and dimensionality in the chemical kinetics of protein filament formation , 2016 .

[110]  Bruno Franchi,et al.  From a Microscopic to a Macroscopic Model for Alzheimer Disease: Two-Scale Homogenization of the Smoluchowski Equation in Perforated Domains , 2016, J. Nonlinear Sci..

[111]  Markus Tolnay,et al.  The propagation of prion-like protein inclusions in neurodegenerative diseases , 2010, Trends in Neurosciences.

[112]  Norbert Schuff,et al.  Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis , 2016, Nature Communications.

[113]  Michele Vendruscolo,et al.  The molecular chaperone Brichos breaks the catalytic cycle that generates toxic Aβ oligomers , 2015, Nature Structural &Molecular Biology.

[114]  D. Kirschner,et al.  On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[115]  E. J. Field,et al.  The infective process in scrapie. , 1968, Lancet.

[116]  Tuomas P. J. Knowles,et al.  Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer’s disease , 2016, Proceedings of the National Academy of Sciences.

[117]  Avner Friedman,et al.  Mathematical model on Alzheimer’s disease , 2016, BMC Systems Biology.

[118]  Michele Vendruscolo,et al.  Molecular mechanisms of protein aggregation from global fitting of kinetic models , 2016, Nature Protocols.